ECSP22020159A - Derivados de piridazin-3(2h)-ona fusionados con azol - Google Patents
Derivados de piridazin-3(2h)-ona fusionados con azolInfo
- Publication number
- ECSP22020159A ECSP22020159A ECSENADI202220159A ECDI202220159A ECSP22020159A EC SP22020159 A ECSP22020159 A EC SP22020159A EC SENADI202220159 A ECSENADI202220159 A EC SENADI202220159A EC DI202220159 A ECDI202220159 A EC DI202220159A EC SP22020159 A ECSP22020159 A EC SP22020159A
- Authority
- EC
- Ecuador
- Prior art keywords
- azole
- derivatives
- fused pyridazine
- compounds
- formula
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Se dan a conocer los compuestos de la fórmula 1: y las sales farmacéuticamente aceptables de los mismos, en donde alfa, ß, n, R4, R5, R6, R8, R9, R10, R11, X1, X2, X3 y X7 se definen en la memoria descriptiva. Esta divulgación también se refiere a los materiales y métodos para la preparación los compuestos de la fórmula 1, a las composiciones farmacéuticas que comprenden los mismos, y a su uso para el tratamiento de las enfermedades, los trastornos y las afecciones asociadas con el GPR139.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962901052P | 2019-09-16 | 2019-09-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP22020159A true ECSP22020159A (es) | 2022-05-31 |
Family
ID=72670806
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECSENADI202220159A ECSP22020159A (es) | 2019-09-16 | 2022-03-16 | Derivados de piridazin-3(2h)-ona fusionados con azol |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US20230028114A1 (es) |
| EP (1) | EP4031552A1 (es) |
| JP (1) | JP2022548602A (es) |
| KR (1) | KR20220063228A (es) |
| CN (1) | CN114728975A (es) |
| AR (1) | AR119971A1 (es) |
| AU (1) | AU2020348675A1 (es) |
| BR (1) | BR112022004819A2 (es) |
| CA (1) | CA3150508A1 (es) |
| CO (1) | CO2022004684A2 (es) |
| CR (1) | CR20220160A (es) |
| DO (1) | DOP2022000057A (es) |
| EC (1) | ECSP22020159A (es) |
| IL (1) | IL291181A (es) |
| JO (1) | JOP20220063A1 (es) |
| MX (1) | MX2022003177A (es) |
| PE (1) | PE20221341A1 (es) |
| TW (1) | TW202124386A (es) |
| WO (1) | WO2021055326A1 (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114149371B (zh) * | 2021-11-26 | 2023-08-22 | 首都医科大学 | 四取代吡唑类化合物及其应用 |
| WO2023165262A1 (zh) * | 2022-03-01 | 2023-09-07 | 上海科技大学 | 噻吩并含氮杂环类化合物、含其的药物组合物、其制备方法及其应用 |
| WO2023165263A1 (zh) * | 2022-03-01 | 2023-09-07 | 上海科技大学 | 吡咯并三嗪酮类化合物、含其的药物组合物、其制备方法及其应用 |
| WO2024121046A1 (en) * | 2022-12-05 | 2024-06-13 | Angelini Pharma S.P.A. | Amide compounds as activators of the potassium channels kv7.2/kv7.3 useful in the treatment of cns and pns disorders |
| CN116063179A (zh) * | 2023-02-20 | 2023-05-05 | 南京杰运医药科技有限公司 | 一种4-甲氧基乙酰乙酸甲酯的合成方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| GB9518953D0 (en) | 1995-09-15 | 1995-11-15 | Pfizer Ltd | Pharmaceutical formulations |
| GB9711643D0 (en) | 1997-06-05 | 1997-07-30 | Janssen Pharmaceutica Nv | Glass thermoplastic systems |
| WO2014152917A2 (en) | 2013-03-14 | 2014-09-25 | Janssen Pharmaceutica Nv | Physiological ligands for gpr139 |
| JO3719B1 (ar) | 2014-11-20 | 2021-01-31 | Takeda Pharmaceuticals Co | 4- أوكسو-4،3- داي هيدرو-3،2،1- بنزوترايازينات كمواد ضابطة لأجل gpr139 |
-
2020
- 2020-09-15 KR KR1020227012292A patent/KR20220063228A/ko active Search and Examination
- 2020-09-15 PE PE2022000427A patent/PE20221341A1/es unknown
- 2020-09-15 CN CN202080079367.0A patent/CN114728975A/zh active Pending
- 2020-09-15 TW TW109131750A patent/TW202124386A/zh unknown
- 2020-09-15 CA CA3150508A patent/CA3150508A1/en active Pending
- 2020-09-15 BR BR112022004819A patent/BR112022004819A2/pt unknown
- 2020-09-15 JP JP2022516328A patent/JP2022548602A/ja active Pending
- 2020-09-15 AU AU2020348675A patent/AU2020348675A1/en active Pending
- 2020-09-15 AR ARP200102558A patent/AR119971A1/es unknown
- 2020-09-15 MX MX2022003177A patent/MX2022003177A/es unknown
- 2020-09-15 US US17/753,803 patent/US20230028114A1/en active Pending
- 2020-09-15 CR CR20220160A patent/CR20220160A/es unknown
- 2020-09-15 EP EP20781670.3A patent/EP4031552A1/en active Pending
- 2020-09-15 JO JOP/2022/0063A patent/JOP20220063A1/ar unknown
- 2020-09-15 WO PCT/US2020/050823 patent/WO2021055326A1/en active Application Filing
-
2022
- 2022-03-08 IL IL291181A patent/IL291181A/en unknown
- 2022-03-15 DO DO2022000057A patent/DOP2022000057A/es unknown
- 2022-03-16 EC ECSENADI202220159A patent/ECSP22020159A/es unknown
- 2022-04-12 CO CONC2022/0004684A patent/CO2022004684A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20230028114A1 (en) | 2023-01-26 |
| AU2020348675A1 (en) | 2022-04-14 |
| CN114728975A (zh) | 2022-07-08 |
| WO2021055326A1 (en) | 2021-03-25 |
| DOP2022000057A (es) | 2022-06-30 |
| IL291181A (en) | 2022-05-01 |
| JP2022548602A (ja) | 2022-11-21 |
| KR20220063228A (ko) | 2022-05-17 |
| CA3150508A1 (en) | 2021-03-25 |
| MX2022003177A (es) | 2022-04-06 |
| JOP20220063A1 (ar) | 2023-01-30 |
| PE20221341A1 (es) | 2022-09-13 |
| BR112022004819A2 (pt) | 2022-06-07 |
| AR119971A1 (es) | 2022-01-26 |
| EP4031552A1 (en) | 2022-07-27 |
| CR20220160A (es) | 2022-06-16 |
| CO2022004684A2 (es) | 2022-07-08 |
| TW202124386A (zh) | 2021-07-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP22020159A (es) | Derivados de piridazin-3(2h)-ona fusionados con azol | |
| CL2021000382A1 (es) | Compuestos novedosos de sulfonamidaurea | |
| CL2019001077A1 (es) | Derivados de 6,7,8,9-tetrahidro-3h-pirazolo[4,3-f] isoquinolina útiles en el tratamiento del cáncer. | |
| CO2020013564A2 (es) | Compuestos heteroaril tetracíclicos | |
| UY37847A (es) | Sulfonilureas y sulfoniltioureas útiles como inhibidores de nlrp3 | |
| UY38001A (es) | Compuestos que inhiben las proteínas ras mutantes g12c | |
| ECSP20062464A (es) | Piperidinil-3-(ariloxi)propanamidas y propanoatos | |
| CL2022000271A1 (es) | Inhibidores de la fosfatasa shp2 de pirazolo(3,4-b)pirazina. | |
| PE20191474A1 (es) | Compuestos de amino-triazolopiridina y su uso en el tratamiento del cancer | |
| UY33921A (es) | Oxazinopteridinas y oxazinoptiridinonas n-sustituidas | |
| UY31068A1 (es) | Ligandos purinoreceptores p2x, metodos para la prparacion de los mismos, composiciones farmaceuticas que los contienen y sus usos 570 | |
| GT200500325A (es) | Pirazolo-pirimidinas 1,4-sustituidas como inhibidores de quinasa | |
| ECSP056194A (es) | Derivados de pirazolo-quinazolina, procedimiento para su preparacion y su uso como inhibidores de quinasa | |
| CO2021005070A2 (es) | Inhibición de la proteasa 30 específica de la ubiquitina (usp30) | |
| BR112016002651A2 (pt) | composto, sal farmaceuticamente aceitável de um composto, composição farmacêutica, combinação, formulação farmacêutica, métodos para exterminar uma micobactéria e/ou inibir a replicação das micobactérias, e para tratar uma infecção e uma doença, e, uso de um composto | |
| CL2021000844A1 (es) | Compuestos de indolinona para uso como inhibidores de map4k1 | |
| UY38228A (es) | Compuestos de triazolopirimidina y su uso en el tratamiento del cáncer | |
| CO2020004977A2 (es) | Compuestos bicíclicos para su uso como inhibidores de la ripi quinasa | |
| DOP2019000070A (es) | Compuestos de azaindazol para usar en lesiones de tendones y/o ligamentos | |
| ECSP19066134A (es) | COMPUESTOS DE TIPO IMIDAZO[4,5-c]QUINOLIN-2-ONA DEUTERADOS Y SU USO EN EL TRATAMIENTO DEL CÁNCER | |
| AR107392A1 (es) | Formulaciones / composiciones que comprenden un inhibidor de btk | |
| CL2022002386A1 (es) | Compuestos de amino pirimidina fusionados | |
| ECSP21080966A (es) | Derivados de 1,1-dióxido de 3-amino-4h-benzo[e][1,2,4] tiadiazina como inhibidores de mrgx2 | |
| UY35945A (es) | Derivados de azaindol | |
| UY39510A (es) | Compuestos macrocíclicos y métodos para usarlos |